Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR.
Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR.
Immunohorizons. 2024 Mar 1;8(3):281-294. doi: 10.4049/immunohorizons.2300079.
Inhibitory proteins, such as programmed cell death protein 1 (PD-1), have been studied extensively in peripheral T cell responses to foreign Ags, self-Ags, and neoantigens. Notably, these proteins are first expressed during T cell development in the thymus. Reports suggest that PD-1 limits regulatory T cell (Treg) development, but the mechanism by which PD-1 exerts this function remains unknown. The present study expands the evaluation of murine PD-1 and its ligands in the thymus, demonstrating that some of the highest expressers of PD-1 and programmed death-ligand 1 are agonist selected cells. Surprisingly, we reveal a selective role for PD-1 in regulating the developmental niche only for Tregs because other agonist selected cell populations, such as NK T cells, remain unchanged. We also ruled out PD-1 as a regulator of proliferation or cell death of agonist selected Tregs and further demonstrated that PD-1-deficient Tregs have reduced TCR signaling. Unexpectedly, the data suggest that PD-1-deficient thymocytes produce elevated levels of IL-2, a Treg niche-limiting cytokine. Collectively, these data suggest a novel role for PD-1 in regulating IL-2 production and the concurrent agonist selection of murine thymic Tregs. This observation has implications for the use of checkpoint blockade in the context of cancer and infection.
抑制蛋白,如程序性细胞死亡蛋白 1(PD-1),已在针对外来抗原、自身抗原和新抗原的外周 T 细胞反应中得到广泛研究。值得注意的是,这些蛋白最初在胸腺中的 T 细胞发育过程中表达。有报道表明,PD-1 限制调节性 T 细胞(Treg)的发育,但 PD-1 发挥此功能的机制仍不清楚。本研究扩展了对小鼠 PD-1 及其配体在胸腺中的评估,表明 PD-1 和程序性死亡配体 1 的一些高表达者是激动剂选择细胞。令人惊讶的是,我们揭示了 PD-1 选择性地仅调节 Treg 的发育龛,因为其他激动剂选择的细胞群体,如 NK T 细胞,保持不变。我们还排除了 PD-1 作为激动剂选择的 Treg 增殖或细胞死亡的调节剂,并进一步证明 PD-1 缺陷的 Treg 具有降低的 TCR 信号。出乎意料的是,数据表明 PD-1 缺陷的胸腺细胞产生高水平的 IL-2,这是 Treg 龛限制细胞因子。总的来说,这些数据表明 PD-1 在调节 IL-2 产生和同时发生的小鼠胸腺 Treg 的激动剂选择中具有新的作用。这一观察结果对在癌症和感染背景下使用检查点阻断具有影响。